Analysts Set $28.50 Target Price for Tigenix NV (TIG)
Tigenix NV (NASDAQ:TIG) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus target price of $28.50 for the company, according to Zacks. Zacks has also assigned Tigenix an industry rank of 104 out of 265 based on the ratings given to its competitors.
TIG has been the topic of a number of recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 price objective (up from $22.00) on shares of Tigenix in a research note on Wednesday, September 20th. BidaskClub lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Finally, Zacks Investment Research lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Saturday, October 21st.
Shares of Tigenix (NASDAQ:TIG) traded up $0.30 during midday trading on Tuesday, reaching $22.70. 15,600 shares of the company traded hands, compared to its average volume of 9,635. Tigenix has a fifty-two week low of $10.77 and a fifty-two week high of $25.72. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.36 and a current ratio of 1.37.
Tigenix Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tigenix NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix NV and related companies with MarketBeat.com's FREE daily email newsletter.